People · Operator
Named in public records as an officer, director or promoter · active 2009–2015 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. | — | Biotechnology | Series C | $201.0M | $3.3B | 2012 |
| Mevion Medical Systems, Inc. | — | Biotechnology | Series C | $95.3M | $2.4B | 2015 |
| NinePoint Medical, Inc. | — | Other Health Care | Series B | $70.4M | $679.4M | 2009 |
| Edimer Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $9.8M | $303.4M | 2013 |
| Selventa, Inc. | — | Other Health Care | Series A | $5.5M | $100.2M | 2011 |
| Ember Therapeutics, Inc. | — | Biotechnology | Seed | $3.2M | $141.7M | 2011 |
Mitchell Bloom at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mitchell Bloom on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Gillis | 2 | 3 |
| Peter Barrett | 1 | 18 |
| Bruce Booth | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| Russell Hirsch | 1 | 10 |
| Michael Grey | 1 | 10 |
| Mark Levin | 1 | 9 |
| David Mott | 1 | 9 |
| Noubar Afeyan | 1 | 9 |
| Robert Wilson | 1 | 7 |
| Mitchell S. Bloom | 1 | 7 |
| Myles Greenberg | 1 | 6 |
| Kevin Starr | 1 | 5 |
| Kenneth Gall | 1 | 5 |
| THOMAS HUGHES | 1 | 4 |
| Arnold Levine | 1 | 4 |
| Anders Hove | 1 | 4 |
| William Aliski | 1 | 4 |
| Cary Pfeffer | 1 | 4 |
| Jay Moorin | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.